The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
Background. Lung cancer (LC) occupies a leading position among malignant tumors in the world, it accounts for 11.4% of the total malignant neoplasms. In 2020, there were 2 206 771 new cases of LC and 1 796 144 deaths worldwide. Among the histological variants, small cell LC (SCLC) has the most unfav...
Enregistré dans:
Auteurs principaux: | Nikolai A. Ognerubov, Tatyana S. Antipova |
---|---|
Format: | article |
Langue: | RU |
Publié: |
IP Habib O.N.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/18767e92e2ff4b289303c8325dfb01d9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
par: Mencinger Marina, et autres
Publié: (2021) -
PET/CT en cáncer pulmonar
par: LADRÓN DE GUEVARA H,DAVID, et autres
Publié: (2010) -
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
par: Seetharamu N, et autres
Publié: (2017) -
Synchronous thyroid gland metastases from breast cancer. Case reports
par: Nikolai A. Ognerubov, et autres
Publié: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)